Trials / Terminated
TerminatedNCT04396236
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 851 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lasmiditan | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2020-06-15
- Primary completion
- 2025-11-12
- Completion
- 2025-11-12
- First posted
- 2020-05-20
- Last updated
- 2026-03-10
Locations
152 sites across 15 countries: United States, Belgium, Canada, France, Germany, India, Italy, Japan, Mexico, Netherlands, Puerto Rico, Romania, Russia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04396236. Inclusion in this directory is not an endorsement.